Comparison of demographic factors between non-participates vs participation by type of trial
| . | Nonparticipants (%) . | Interventional therapeutic trial all (%) . | P value (α = unadjusted) . | Interventional nontherapeutic only . | P value (α = unadjusted) . | Noninterventional trial only . | P value (α = unadjusted) . |
|---|---|---|---|---|---|---|---|
| n | 2196 | 646 | 69 | 235 | |||
| Sex | |||||||
| Female | 926 (42.2) | 228 (35.3) | .75 | 33 (47.8) | .39 | 87 (37) | .81 |
| Male | 1270 (57.8) | 418 (64.7) | 36 (52.2) | 148 (63) | |||
| Age | |||||||
| Mean | 63 | 61 | .001 | 60 | .062 | 63 | .86 |
| SD | 14.7 | 13.3 | 14.6 | 16.4 | |||
| Median | 65 | 62 | 62 | 65 | |||
| Ethnicity | |||||||
| Hispanic/Latino | 301 (13.7) | 74 (11.5) | .17 | 8 (11.6) | .74 | 28 (11.9) | .67 |
| Non-Hispanic (NH) | 1838 (83.7) | 560 (86.7) | 60 (87) | 202 (86) | |||
| Unknown | 57 (2.6) | 12 (1.9) | 1 (1.4) | 5 (2.1) | |||
| Race | |||||||
| NH White | 1614 (73) | 505 (78.2) | .22 | 55 (79.7) | .63 | 182 (77.4) | .76 |
| Hispanic/Latino | 301 (13.7) | 74 (11.5) | 8 (11.6) | 28 (11.9) | |||
| Non-Hispanic Black/AA | 139 (6.3) | 33 (5.1) | 4 (5.8) | 13 (5.5) | |||
| Non-Hispanic Asian | 87 (3) | 20 (3.1) | 2 (2.9) | 7 (3) | |||
| Other/unknown | 55 (2.5) | 14 (2.2) | 0 (0) | 5 (2.1) | |||
| Diagnosis | |||||||
| DLBCL | 658 (30.0) | 162 (25) | .0005 | 18 (26) | 0.58 | 79 (33.6) | .0005 |
| FL | 544 (24.8) | 114 (17.6) | 21 (30.4) | 19 (8.1) | |||
| MCL | 189 (8.6) | 207 (32) | 4 (5.8) | 17 (7.2) | |||
| MZL | 214 (10.6) | 24 (3.7) | 10 (14.5) | 21 (8.9) | |||
| TCL | 157 (7.1) | 79 (12.2) | 4 (5.8) | 19 (8.1) | |||
| Misc. | 186 (8.5) | 10 (1.5) | 8 (11.6) | 31 (13.2) | |||
| High Grade BCL | 142 (6.5) | 26 (4) | 4 (5.8) | 33 (14) | |||
| Composite | 79 (3.6) | 23 (3.6) | 0 (0) | 16 (6.8) | |||
| Gray Zone lymphoma | 9 (0.4) | 1 (0.2) | 0 (0) | 0 (0) | |||
| Insurance type | |||||||
| Private insurance / managed Care | 1032 (47) | 332 (51.4) | .37 | 40 (58) | .25 | 100 (42.6) | .19 |
| Medicare | 1027 (46.8) | 278 (43) | 28 (40) | 119 (50.6) | |||
| Medicaid | 25 (1.1) | 7 (1.1) | 0 (0) | 4 (1.7) | |||
| Self-pay | 62 (2.8) | 14 (2.2) | 1 (1.4) | 3 (1.3) | |||
| Government/other | 50 (2.3) | 15 (2.3) | 0 (0) | 9 (3.8) | |||
| ADI (quartiles) | n = 2009 | n = 598 | N = 219 | ||||
| Q1 (0-25) | 514 (25.6) | 191 (31.9) | .007 | 18 (29) | .85 | 51 (23.3) | .52 |
| Q2 (26-50) | 610 (30.4) | 185 (30.9) | 20 (32.2) | 74 (33.8) | |||
| Q3 (51-75) | 545 (27.1) | 141 (23.6) | 14 (22.6) | 53 (24.2) | |||
| Q4 (76-100) | 340 (16.9) | 81 (13.5) | 10 (16.1) | 41 (18.7) | |||
| ADI (continuous) | |||||||
| Mean | 46 | 42 | 0.001 | 44 | 0.54 | 47.3 | 0.86 |
| SD | 26.2 | 25.9 | 26 | 26.5 | |||
| Median | 45 | 41 | 40 | 44 |
| . | Nonparticipants (%) . | Interventional therapeutic trial all (%) . | P value (α = unadjusted) . | Interventional nontherapeutic only . | P value (α = unadjusted) . | Noninterventional trial only . | P value (α = unadjusted) . |
|---|---|---|---|---|---|---|---|
| n | 2196 | 646 | 69 | 235 | |||
| Sex | |||||||
| Female | 926 (42.2) | 228 (35.3) | .75 | 33 (47.8) | .39 | 87 (37) | .81 |
| Male | 1270 (57.8) | 418 (64.7) | 36 (52.2) | 148 (63) | |||
| Age | |||||||
| Mean | 63 | 61 | .001 | 60 | .062 | 63 | .86 |
| SD | 14.7 | 13.3 | 14.6 | 16.4 | |||
| Median | 65 | 62 | 62 | 65 | |||
| Ethnicity | |||||||
| Hispanic/Latino | 301 (13.7) | 74 (11.5) | .17 | 8 (11.6) | .74 | 28 (11.9) | .67 |
| Non-Hispanic (NH) | 1838 (83.7) | 560 (86.7) | 60 (87) | 202 (86) | |||
| Unknown | 57 (2.6) | 12 (1.9) | 1 (1.4) | 5 (2.1) | |||
| Race | |||||||
| NH White | 1614 (73) | 505 (78.2) | .22 | 55 (79.7) | .63 | 182 (77.4) | .76 |
| Hispanic/Latino | 301 (13.7) | 74 (11.5) | 8 (11.6) | 28 (11.9) | |||
| Non-Hispanic Black/AA | 139 (6.3) | 33 (5.1) | 4 (5.8) | 13 (5.5) | |||
| Non-Hispanic Asian | 87 (3) | 20 (3.1) | 2 (2.9) | 7 (3) | |||
| Other/unknown | 55 (2.5) | 14 (2.2) | 0 (0) | 5 (2.1) | |||
| Diagnosis | |||||||
| DLBCL | 658 (30.0) | 162 (25) | .0005 | 18 (26) | 0.58 | 79 (33.6) | .0005 |
| FL | 544 (24.8) | 114 (17.6) | 21 (30.4) | 19 (8.1) | |||
| MCL | 189 (8.6) | 207 (32) | 4 (5.8) | 17 (7.2) | |||
| MZL | 214 (10.6) | 24 (3.7) | 10 (14.5) | 21 (8.9) | |||
| TCL | 157 (7.1) | 79 (12.2) | 4 (5.8) | 19 (8.1) | |||
| Misc. | 186 (8.5) | 10 (1.5) | 8 (11.6) | 31 (13.2) | |||
| High Grade BCL | 142 (6.5) | 26 (4) | 4 (5.8) | 33 (14) | |||
| Composite | 79 (3.6) | 23 (3.6) | 0 (0) | 16 (6.8) | |||
| Gray Zone lymphoma | 9 (0.4) | 1 (0.2) | 0 (0) | 0 (0) | |||
| Insurance type | |||||||
| Private insurance / managed Care | 1032 (47) | 332 (51.4) | .37 | 40 (58) | .25 | 100 (42.6) | .19 |
| Medicare | 1027 (46.8) | 278 (43) | 28 (40) | 119 (50.6) | |||
| Medicaid | 25 (1.1) | 7 (1.1) | 0 (0) | 4 (1.7) | |||
| Self-pay | 62 (2.8) | 14 (2.2) | 1 (1.4) | 3 (1.3) | |||
| Government/other | 50 (2.3) | 15 (2.3) | 0 (0) | 9 (3.8) | |||
| ADI (quartiles) | n = 2009 | n = 598 | N = 219 | ||||
| Q1 (0-25) | 514 (25.6) | 191 (31.9) | .007 | 18 (29) | .85 | 51 (23.3) | .52 |
| Q2 (26-50) | 610 (30.4) | 185 (30.9) | 20 (32.2) | 74 (33.8) | |||
| Q3 (51-75) | 545 (27.1) | 141 (23.6) | 14 (22.6) | 53 (24.2) | |||
| Q4 (76-100) | 340 (16.9) | 81 (13.5) | 10 (16.1) | 41 (18.7) | |||
| ADI (continuous) | |||||||
| Mean | 46 | 42 | 0.001 | 44 | 0.54 | 47.3 | 0.86 |
| SD | 26.2 | 25.9 | 26 | 26.5 | |||
| Median | 45 | 41 | 40 | 44 |
Bold values denote statistical significance at the P value < .05 level.
AA, African American; BCL, B-cell lymphoma; MCL, mantle cell lymphoma; MZL, Marginal zone lymphoma; TCL, T-cell lymphoma.